• Explore /
  • Poster
  • / BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

Abstract Poster

Authors

Keunchil Park

Keunchil Park

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, The Republic of

Keunchil Park , Jong-Seok Lee , Ki Hyeong Lee , Joo-Hang Kim , Byoung Chul Cho , Young Joo Min , Jae Yong Cho , Ji-Youn Han , Bong-Seog Kim , Jin-Soo Kim , Dae Ho Lee , Jin Hyoung Kang , Eun Kyung Cho , Hoon-Gu Kim , Kyung Hee Lee , Hoon Kyo Kim , In-Jin Jang , Hyo-Yeon Kim , Jeewoong Son , Dong-Wan Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01588145

Citation

J Clin Oncol 34, 2016 (suppl; abstr 9055)

DOI

10.1200/JCO.2016.34.15_suppl.9055

Abstract #

9055

Poster Bd #

378

Abstract Disclosures

Similar Posters

First Author: Qing Zhou

First Author: Yi-Long Wu

First Author: Hiroshige Yoshioka

First Author: Naoki Furuya